Premium
Alcohol Medications Development: Advantages and Caveats of Government/Academia Collaborating with the Pharmaceutical Industry
Author(s) -
Litten Raye Z.,
Ryan Megan,
Falk Daniel,
Fertig Joanne
Publication year - 2014
Publication title -
alcoholism: clinical and experimental research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.267
H-Index - 153
eISSN - 1530-0277
pISSN - 0145-6008
DOI - 10.1111/acer.12357
Subject(s) - expediting , government (linguistics) , mainstream , pharmaceutical industry , business , process (computing) , public relations , medicine , political science , management , pharmacology , economics , linguistics , philosophy , computer science , law , operating system
The process of developing pharmacological treatments for alcohol use disorder is notoriously complex and challenging. The path to market is long, costly, and inefficient. One way of expediting and reducing the drug development process is through collaborations—building partnerships among government, academia, pharmaceutical and biotechnology companies, healthcare organizations and advocacy groups, and the patients (end consumers) themselves. By forging collaborations, particularly with pharmaceutical companies, the alcohol treatment field stands to reap benefits in generating new medications for use in mainstream treatment settings. At the same time, there are certain caveats that should be considered, particularly by academic researchers, before entering into such partnerships. This commentary examines the advantages and caveats of government and academia collaborations with pharmaceutical companies.